Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Outlook Therapeutics (OTLK) Equity Average (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Equity Average for 7 consecutive years, with -$35.4 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 79.88% to -$35.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$35.4 million through Dec 2025, down 79.88% year-over-year, with the annual reading at -$20.8 million for FY2019, 29.6% up from the prior year.
  • Equity Average for Q4 2025 was -$35.4 million at Outlook Therapeutics, down from -$34.7 million in the prior quarter.
  • The five-year high for Equity Average was -$19.7 million in Q4 2024, with the low at -$41.4 million in Q1 2025.